

7-13-06


IPD

Please type a plus sign (+) inside this box ☐

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		<b>Application Number</b>	10/575,291	
		<b>Filing Date</b>	April 11, 2006	
		<b>First Named Inventor</b>	Kingston Mills et al.	
		<b>Group/Art Unit</b>	Unassigned	
		<b>Examiner Name</b>	Unassigned	
<b>Total Number of Pages in This Submission</b>			<b>Attorney Docket Number</b>	43369-0001

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> Exhibits <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input checked="" type="checkbox"/> <b>Information Disclosure Statement w/8 References</b> <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Status Claimed <input type="checkbox"/> Statement under 3.73(b)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> <b>COPY OF PCT SEARCH REPORT AND RETURN STAMPED POSTCARD</b> </div>
<div style="border: 1px solid black; padding: 5px;"> <b>Remarks</b>   <b>AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 (ATTORNEY DOCKET NO.: 43369-0001) FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER.</b> </div>		


## SIGNATURE OF APPLICANT, ATTORNEY OR AGENT


<b>Firm or Individual name</b>	James A. Fox, Reg. No. 38,455, HELLER EHRMAN LLP		
<b>Signature</b>			
<b>Date</b>	July 11, 2006	<b>Customer Number:</b>	25213

## CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: xxxxxx; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450			
Express Mail Label: EV 765 972 865 US			
<b>Typed or printed name</b>	Elena Torres		
<b>Signature</b>		<b>Date</b>	July 11, 2006

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop \_\_\_, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



CERTIFICATE OF EXPRESS MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA on the date indicated below.			
		Express Mail Label: EV 765 972 865 US	
Typed or print name	Elena Torres		
Signature		Date	July 11, 2006

PATENT

Attorney Docket No.: 43369-0001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**PATENT APPLICATION**

Inventor(s): Kingston Mills et al.

Application No.: 10/575,291

Filed: April 11, 2006

Title: FILAMENTOUS HAEMAGGLUTININ IN THE  
TREATMENT AND/OR PROPHYLAXIS OF  
IMMUNE-MEDIATED DISORDERS

Art Unit: Unassigned

Examiner: Unassigned

**INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. §1.97**

Mail Stop: AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☒ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 43369-0001).

Respectfully submitted,

HELLER EHRMAN LLP

Dated: July 11, 2006

By: 

JAMES A. FOX  
Reg. No.: 38,455

HELLER EHRMAN LLP  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
Telephone: 1.650.324.7115  
Facsimile: 1.650.324.0638  
Customer No.: 25213

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>		ATTY. DOCKET NO. 43369-0001		SERIAL NO. 10/575,291			
		APPLICANT: Kingston Mills, et al.					
		FILING DATE: 04/11/2006		GROUP: Unassigned			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 267 998	17-11.1986	EP			<input type="checkbox"/>	<input type="checkbox"/>
	0 336 736	04.04.1989	EP			<input type="checkbox"/>	<input type="checkbox"/>
	0 471 177	02.07.1991	EP			<input type="checkbox"/>	<input type="checkbox"/>
	01/93906	13.12.2001	WO			<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
Harrison L C et al., "Antigen-Specific Therapy for Autoimmune Disease", Current Opinion in Immunology, Current Biology LTD, XX, vol. 12, no. 6, pp. 704-711, 2000, XP004257746.							
McGuirk, Peter et al., " Filamentous Hemagglutinin and Pertussis Toxin from Bordetella Pertussis Modulate Immune Responses to Unrelated Antigens", Journal of Infectious Diseases, vol. 182, no. 4, pp. 1286-1288, October 2000, XP009042214.							
McGuirk, Peter et al., "Direct Anti-Inflammatory Effect of a Bacterial Virulence Factor: IL-10-Dependent Suppression of IL-12 Production by Filamentous Hemagglutinin from Bordetella Pertussis", European Journal of Immunology, vol. 30, no. 2, pp. 415-422, 2000, XP002312759.							
Poulain-Godefroy O et al., "Adjuvant Effect of Bordetella Pertussis Filamentous Hemagglutinin in Association with Liposomes for Vaccine Intranasal Delivery", Immunology Letters, Amsterdam, NL, vol. 69, no. 1, pp. 59-60, 1999, XP000982125.							
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.